EUVIMEDEUVIMED entdecken
Systematische Übersicht

Cannabinoids in the treatment of chronic pain: current evidence on efficacy, safety, and pharmacogenetic aspects (a systematic review)

O. A. Kicherova, S. D. Bashan, K. P. Kicherova, L. I. Reikhert

Perm Medical Journal · 07.11.2026 · 43 (5) · 17-31

DOI: 10.17816/pmj43517-31 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Perm Medical Journal, online erschienen am 07.11.2026. Verfasst von O. A. Kicherova und 3 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current evidence-based data on the efficacy and safety of cannabinoids in various forms of chronic pain, and are systematized, and the role of pharmacogenetic factors in personalizing therapy is assessed. An analysis of the literature for the period 2013–2026 was conducted using PubMed, Cochrane Library, and Google Scholar. The review included systematic reviews, meta-analyses, randomized controlled trials, and clinical guidelines from leading international organizations (IASP, ACP, NICE, AHRQ). The most convincing evidence for the efficacy of cannabinoids exists for chronic neuropathic pain, predominantly for preparations containing tetrahydrocannabinol (THC) or a combination of THC and cannabidiol (CBD). The magnitude of the analgesic effect remains moderate and corresponds to a reduction in pain intensity of less than 1 point on a 10-point scale. For other common pain syndromes – chronic low back pain, osteoarthritis, fibromyalgia, and most types of cancer pain – the evidence is insufficient. Nevertheless, even such a small reduction may be clinically meaningful for individual patients with resistant pain. It has been shown that genetic polymorphisms (in particular, CNR1, FAAH, ABCB1, TRPV1, UGT2B7) may influence the efficacy and risk of adverse events with cannabinoid therapy. The safety profile is characterized by a high incidence of adverse effects, especially with THC-containing preparations; CBD monotherapy demonstrates a more favorable profile, but convincing clinical evidence of the standalone analgesic efficacy of CBD in chronic pain is currently insufficient. Cannabinoids should not be considered first-line therapy for chronic pain. Their use may be justified only in carefully selected patients with resistant neuropathic pain syndromes as second- or third-line adjunctive therapy with mandatory monitoring of efficacy and safety. Research into the role of pharmacogenetic testing for personalized therapy is a promising direction.

Zitieren

APA

Kicherova, O. A., Bashan, S. D., Kicherova, K. P., & Reikhert, L. I. (2026). Cannabinoids in the treatment of chronic pain: current evidence on efficacy, safety, and pharmacogenetic aspects (a systematic review). Perm Medical Journal, 43(5), 17-31. https://doi.org/10.17816/pmj43517-31

Vancouver

Kicherova OA, Bashan SD, Kicherova KP, Reikhert LI. Cannabinoids in the treatment of chronic pain: current evidence on efficacy, safety, and pharmacogenetic aspects (a systematic review). Perm Medical Journal. 2026;43(5):17-31. doi:10.17816/pmj43517-31

BibTeX
@article{Kicherova2026,
  author = {Kicherova, O. A. and Bashan, S. D. and Kicherova, K. P. and Reikhert, L. I.},
  title = {Cannabinoids in the treatment of chronic pain: current evidence on efficacy, safety, and pharmacogenetic aspects (a systematic review)},
  journal = {Perm Medical Journal},
  year = {2026},
  volume = {43},
  number = {5},
  pages = {17--31},
  doi = {10.17816/pmj43517-31}
}
Kostenlos starten →